Cedars Sinai

Health Tech

How Cedars-Sinai, Evernorth & More Are Deploying AI Responsibly

While the dawn of a new AI age is certainly exciting, healthcare leaders are still concerned that the industry lacks a comprehensive framework to regulate these new tools. In the absence of these guidelines, healthcare executives are creating their own governance strategies to deploy AI responsibly, executives said during a panel discussion on Thursday at MedCity News’ INVEST Digital Health conference in Dallas.

presented by
Health Tech

Cedars-Sinai’s CMIO Has A Piece of Advice for AI Startups

At HLTH, Shaun Miller — Cedars-Sinai's chief medical information officer — pointed out one thing he thinks healthcare AI companies haven’t quite gotten right yet. He said he would “really like there to be a lot more recognition around the personalization of AI and the ability for technology to understand that not every clinician is the same.”

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.